Sorrento up on FDA clearance for cancer therapy trial

Sorrento Therapeutics

17/05/2022 16:53

** Shares of Sorrento Therapeutics  SRNE.O  rise 5.9% to
$1.52
    ** Receives FDA clearance to start mid-stage study of
Abivertinib in metastatic castrate resistant prostate cancer
 urn:newsml:reuters.com:*:nFWN2X90QV
    ** Separately, SRNE says license partner China Oncology
Focus Ltd has completed enrollment in late-stage trial testing
monoclonal antibody discovered by SRNE in type of lung cancer
    ** Stock down ~67% YTD, including session moves

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))